CCI Clears Adani Powers Acquisition of Coastal Energen and Matrix Pharmas Acquisition of Tianish Labs

The Competition Commission of India (CCI) has approved Adani Power Limited's (APL) proposal to acquire a 100% stake in Coastal Energen Private Limited (CEPL). The acquisition involves the purchase of the entire equity share capital of CEPL by APL and Dickey Alternative Investment Trust (DAIT), a Sebi-registered Alternative Investment Fund (AIF).

Representative image

APL, a subsidiary of the Adani Group, is India's leading private-sector thermal power producer. CEPL, on the other hand, is engaged in the generation and sale of power and is currently undergoing a Corporate Insolvency Resolution Process (CIRP) under the Insolvency and Bankruptcy Code.

CCI Greenlights Matrix Pharma's Acquisition of Tianish Laboratories

In a separate development, CCI has also approved Matrix Pharma Private Limited's proposal to acquire a 100% shareholding of Tianish Laboratories Private Limited. Tianish Laboratories is involved in the manufacturing and sale of active pharmaceutical ingredients in India.

Matrix Pharma, which currently does not have any business operations in India or abroad, intends to purchase the entire equity shares of Tianish Laboratories. Prior to the acquisition, Kotak Strategic Situations India Fund II and Kotak Alternate Asset Managers, both Sebi-registered AIFs, will subscribe to certain optionally convertible debentures of Matrix Pharma.

The proceeds from this investment will be utilized by Matrix Pharma to fund its acquisition of Tianish Laboratories. Kotak Strategic Situations India Fund II is a Sebi-registered AIF, while Kotak Alternate Asset Managers acts as an investment manager, engaged in the business of managing and advising funds.

Significance of CCI Approvals

The Competition Commission of India plays a crucial role in regulating business practices and promoting fair competition in the Indian marketplace. Deals that exceed a certain threshold require approval from the regulator to ensure that they do not result in unfair business practices or hinder market competition.

The CCI's approval of Adani Power's acquisition of Coastal Energen and Matrix Pharma's acquisition of Tianish Laboratories signifies the regulator's assessment that these transactions align with the principles of fair competition and do not pose any significant concerns in terms of market dominance or anti-competitive behavior.